

# CITATION REPORT

List of articles citing

## Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence

DOI: 10.2165/00003088-200544070-00001  
Clinical Pharmacokinetics, 2005, 44, 661-80.

**Source:** <https://exaly.com/paper-pdf/39421297/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
230	Does high-dose buprenorphine cause respiratory depression?: possible mechanisms and therapeutic consequences. <b>2006</b> , 25, 79-85		71
229	Management of Cancer Pain. <b>2006</b> , 5, 171-182		5
228	Effect of opioid substitution therapy on alcohol metabolism. <b>2006</b> , 30, 191-6		10
227	Endogenous opiates and behavior: 2005. <b>2006</b> , 27, 3391-478		59
226	Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials. <b>2006</b> , 46, 179-92		45
225	Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. <b>2007</b> , 35, 1232-8		61
224	Pharmacokinetics of buprenorphine: a comparison of sublingual tablet versus liquid after chronic dosing. <b>2007</b> , 1, 88-95		7
223	Opioid maintenance: a comparative review of pharmacological strategies. <b>2007</b> , 8, 1-11		20
222	Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics. <i>Clinical Pharmacokinetics</i> , <b>2007</b> , 46, 825-50	6.2	36
221	Poor Man's Smack: A Qualitative Study of Buprenorphine Injecting in Melbourne, Australia. <b>2007</b> , 34, 525-548		2
220	Simultaneous determination of methadone, buprenorphine and norbuprenorphine in biological fluids for therapeutic drug monitoring purposes. <b>2007</b> , 847, 95-102		30
219	Erweiterung des GPP Konsensus-Papiers "Substanzabhängigkeit vom Morphintyp" – State-of-the-art der Erhaltungstherapie mit synthetischen Opioiden": Die Therapie mit einem Buprenorphin/Naloxon-Kombinationspräparat. <b>2008</b> , 4, 69-73		
218	Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. <b>2008</b> , 392, 1093-108		430
217	Opioid addiction and pregnancy: perinatal exposure to buprenorphine affects myelination in the developing brain. <b>2008</b> , 56, 1017-27		92
216	Opioid analgesics and narcotic antagonists. <b>2008</b> , 30, 106-124		
215	Urinary excretion of buprenorphine, norbuprenorphine, buprenorphine-glucuronide, and norbuprenorphine-glucuronide in pregnant women receiving buprenorphine maintenance treatment. <b>2009</b> , 55, 1177-87		29
214	Increased prevalence of metabolic syndrome in individuals with osteoarthritis: an analysis of NHANES III data. <b>2009</b> , 121, 9-20		201

213	Memory function in opioid-dependent patients treated with methadone or buprenorphine along with benzodiazepine: longitudinal change in comparison to healthy individuals. <b>2009</b> , 4, 6	26
212	The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence. <b>2009</b> , 10, 2537-44	29
211	Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. <b>2009</b> , 103, 37-43	56
210	Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. <b>2009</b> , 105, 234-9	21
209	Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence. <b>2009</b> , 69, 577-607	96
208	Inadequate Dose of Opioid-agonist Medication is Related to Misuse of Benzodiazepines. <b>2009</b> , 8, 145-153	4
207	Comparison of five benzodiazepine-receptor agonists on buprenorphine-induced mu-opioid receptor regulation. <b>2009</b> , 110, 36-46	22
206	Neurobiologie de la toxicomanie : avancées récentes et nouvelles stratégies d'intervention. <b>2009</b> , 8, 27-73	1
205	Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. <b>2010</b> , 54, 511-4	15
204	Buprenorphine and major metabolites in blood specimens collected for drug analysis in law enforcement purposes. <b>2010</b> , 195, 73-7	9
203	An in vitro approach to estimate putative inhibition of buprenorphine and norbuprenorphine glucuronidation. <b>2010</b> , 124, 187-94	14
202	Effect of cocaine use on buprenorphine pharmacokinetics in humans. <b>2010</b> , 19, 38-46	14
201	Testing for illicit drug use in mental health services. <b>2010</b> , 16, 369-379	8
200	Nurses' Knowledge about Pain Management with Opioids for Dying Patients United Kingdom Nursing Perspective. <b>2010</b> , 24, 275-286	1
199	Differential activation of pregnane X receptor and constitutive androstane receptor by buprenorphine in primary human hepatocytes and HepG2 cells. <b>2010</b> , 335, 562-71	14
198	Screening for drugs of abuse: which matrix, oral fluid or urine?. <b>2011</b> , 48, 531-41	50
197	Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing. <b>2011</b> , 118, 265-73	53
196	Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. <b>2011</b> , 4, 28-41	242

195	Therapeutic drug monitoring for drugs used in the treatment of substance-related disorders: literature review using a therapeutic drug monitoring appropriateness rating scale. <b>2011</b> , 33, 561-72	20
194	Inhibition of human drug metabolizing cytochrome P450 enzymes by plant isoquinoline alkaloids. <b>2011</b> , 18, 533-8	31
193	Management of women treated with buprenorphine during pregnancy. <b>2011</b> , 205, 302-8	24
192	Development and validation of a method for the determination of buprenorphine and norbuprenorphine in breast milk by gas chromatography-mass spectrometry. <b>2012</b> , 26, 358-62	7
191	Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential?. <b>2011</b> , 44, 250-68	20
190	Unusual false-positive case of urinary screening for buprenorphine. <b>2011</b> , 25, 244-5	7
189	LC-MS-MS analysis of buprenorphine and norbuprenorphine in whole blood from suspected drug users. <b>2011</b> , 209, 113-9	17
188	Efficacy of oral transmucosal and intravenous administration of buprenorphine before surgery for postoperative analgesia in dogs undergoing ovariohysterectomy. <b>2011</b> , 238, 318-28	40
187	Buprenorphine exposure in infants of opioid-dependent mothers at birth. <b>2012</b> , 52, 342-7	12
186	Toxicological and pathological findings in a series of buprenorphine related deaths. Possible risk factors for fatal outcome. <b>2012</b> , 220, 284-90	51
185	Analgesics in patients with hepatic impairment: pharmacology and clinical implications. <b>2012</b> , 72, 1645-69	113
184	Buprenorphine. <b>2012</b> , 514-526	
183	Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning. <b>2012</b> , 68, 301-9	99
182	Parenteral buprenorphine-naloxone abuse is a major cause of fatal buprenorphine-related poisoning. <b>2013</b> , 232, 11-5	23
181	Initiation of buprenorphine during incarceration and retention in treatment upon release. <b>2013</b> , 45, 222-6	46
180	Pharmacologically active drug metabolites: impact on drug discovery and pharmacotherapy. <b>2013</b> , 65, 578-640	100
179	Buprenorphine. <b>2013</b> , 45, 939-49	30
178	Medication-assisted treatment for opioid addiction: methadone and buprenorphine. <b>2013</b> , 21, S69-S72	28

177	Buprenorphine and norbuprenorphine quantification in human plasma by simple protein precipitation and ultra-high performance liquid chromatography tandem mass spectrometry. <b>2013</b> , 77, 1-8	18
176	Treatment of Opioid Dependence. <b>2013</b> , 61-102	3
175	The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. <b>2013</b> , 63, 480-4	12
174	Buprenorphine for treating cancer pain. <b>2013</b> ,	2
173	Buprenorphine-naloxone treatment in opioid dependence and risk of liver enzyme elevation: results from a 12-month observational study. <b>2014</b> , 23, 563-9	8
172	Differential diagnosis for a stable patient maintained on buprenorphine who gives a urine toxicology screen negative for buprenorphine. <b>2014</b> , 23, 318-9	3
171	A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine. <b>2014</b> , 348, 217-26	28
170	Perioperative analgesia and challenges in the drug-addicted and drug-dependent patient. <b>2014</b> , 28, 91-101	46
169	Pharmakokinetische Wechselwirkungen illegaler Drogen mit Arzneimitteln. <b>2014</b> , 24, 77-90	2
168	Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioid-dependent individuals. <b>2014</b> , 23, 34-40	8
167	Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy. <b>2014</b> , 144, 1-11	78
166	Addendum: A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice. <b>2014</b> , 9,	15
165	Hollow fiber liquid-phase microextraction combined with ultra-high performance liquid chromatography-tandem mass spectrometry for the simultaneous determination of naloxone, buprenorphine and norbuprenorphine in human plasma. <b>2014</b> , 951-952, 157-63	20
164	Respiratory effects of buprenorphine/naloxone alone and in combination with diazepam in naive and tolerant rats. <b>2014</b> , 228, 75-84	10
163	Case Studies in Pain Management. 373-378	
162	Case Studies in Pain Management. 442-446	
161	Buprenorphine for neuropathic pain in adults. <b>2015</b> ,	41
160	Buprenorphine for treating cancer pain. <b>2015</b> , CD009596	28

159	Genetic determinants of fetal opiate exposure and risk of neonatal abstinence syndrome: Knowledge deficits and prospects for future research. <i>Clinical Pharmacology and Therapeutics</i> , <b>2015</b> , 98, 309-20	6.1	16
158	Buprenorphine for neuropathic pain in adults. <b>2015</b> , CD011603		18
157	Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome. <b>2015</b> , 35, 670-80		29
156	Opiate addiction therapies and HIV-1 Tat: interactive effects on glial [Ca <sup>2+</sup> ] <sub>i</sub> , oxyradical and neuroinflammatory chemokine production and correlative neurotoxicity. <b>2014</b> , 12, 424-34		19
155	Effect of steady-state faldaprevir on the pharmacokinetics of steady-state methadone and buprenorphine-naloxone in subjects receiving stable addiction management therapy. <b>2015</b> , 59, 498-504		4
154	A Multidisciplinary Approach to the Treatment of Co-occurring Opioid Use Disorder and Posttraumatic Stress Disorder in Pregnancy: A Case Report. <b>2015</b> , 11, 248-57		56
153	Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy. <b>2015</b> , 71, 303-11		18
152	Partial hepatectomy in mice. <b>2015</b> , 49, 81-8		23
151	Clinical pharmacology profile of boceprevir, a hepatitis C virus NS3 protease inhibitor: focus on drug-drug interactions. <i>Clinical Pharmacokinetics</i> , <b>2015</b> , 54, 599-614	6.2	4
150	Buprenorphine. <b>2016</b> , 1079-1087		
149	Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy Subjects. <b>2016</b> , 56, 1263-71		8
148	Managing Opioid-Tolerant Patients in the Perioperative Surgical Home. <b>2016</b> , 34, 287-301		35
147	Neuropsychiatric pharmaceuticals and illicit drugs in wastewater treatment plants: a review. <b>2016</b> , 13, 541		29
146	Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. <b>2016</b> , 12, 721-31		8
145	The New Kid on the Block--Incorporating Buprenorphine into a Medical Toxicology Practice. <b>2016</b> , 12, 64-70		5
144	Maternal Buprenorphine Maintenance and Lactation. <b>2016</b> , 32, 675-681		26
143	Predictors of neonatal abstinence syndrome in buprenorphine exposed newborn: can cord blood buprenorphine metabolite levels help?. <b>2016</b> , 5, 854		5
142	Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction. <b>2016</b> , 72, 1363-1371		12

141	Improving the oral bioavailability of buprenorphine: an in-vivo proof of concept. <b>2017</b> , 69, 23-31	3
140	Opioid receptor agonists. <b>2016</b> , 348-380	
139	Buprenorphine--the unique opioid adjuvant in regional anesthesia. <b>2016</b> , 9, 375-83	14
138	How Does In Vivo Biliary Elimination of Drugs Change with Age? Evidence from In Vitro and Clinical Data Using a Systems Pharmacology Approach. <b>2016</b> , 44, 1090-8	19
137	New Pain Management Options for the Surgical Patient on Methadone and Buprenorphine. <b>2016</b> , 20, 16	36
136	Breakthrough Pain Associated with a Reduction in Serum Buprenorphine Concentration during Dialysis. <b>2016</b> , 38, 212-5	4
135	The effectiveness of buprenorphine for treating cancer pain: an abridged Cochrane review. <b>2016</b> , 6, 292-306	7
134	Pharmacokinetics of buprenorphine following constant rate infusion for postoperative analgesia in dogs undergoing ovariectomy. <b>2017</b> , 44, 435-443	2
133	Probuphine <sup>®</sup> (buprenorphine implant): a promising candidate in opioid dependence. <b>2017</b> , 7, 119-134	23
132	Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes: Executive Summary of a Joint Workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, American College of Obstetricians and Gynecologists, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, Centers for Disease Control and Prevention, and the March of Dimes Foundation. <b>2017</b> , 120, 10-38	133
131	Buprenorphine for managing opioid withdrawal. <b>2017</b> , 2, CD002025	49
130	Inhibition of glucuronidation and oxidative metabolism of buprenorphine using GRAS compounds or dietary constituents/supplements: in vitro proof of concept. <b>2017</b> , 38, 139-154	7
129	Naltrexone- or Nalmefene-Related Buprenorphine Withdrawal: Treat It With More Buprenorphine. <b>2017</b> , 37, 631-633	2
128	Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. <b>2017</b> , 18, 1987-1999	67
127	Practical Management of the Opioid-Tolerant Patient in the Perioperative Surgical Home. <b>2017</b> , 35, 175-190	4
126	High prevalence of urine tampering in an office-based opioid treatment practice detected by evaluating the norbuprenorphine to buprenorphine ratio. <b>2017</b> , 83, 62-67	8
125	Do all screening immunoassay positive buprenorphine samples need to be confirmed?. <b>2017</b> , 54, 707-711	3
124	An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy. <b>2017</b> , 217, 459.e1-459.e6	28

123	Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy. <b>2017</b> , 216, 64.e1-64.e7		31
122	C-Homomorphinan Derivatives as Lead Compounds to Obtain Safer and More Clinically Useful Analgesics. <b>2017</b> , 65, 920-929		6
121	Advances in the delivery of buprenorphine for opioid dependence. <b>2017</b> , 11, 2493-2505		38
120	Magnetic molecularly imprinted polymer nanoparticles for dispersive micro solid-phase extraction and determination of buprenorphine in human urine samples by HPLC-FL. <b>2018</b> , 15, 1569-1580		6
119	Implementation of a pharmacist-led pharmacogenomics service for the Program of All-Inclusive Care for the Elderly (PHARM-GENOME-PACE). <b>2018</b> , 58, 281-289.e1		21
118	Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder. <b>2018</b> , 14, 475-482		10
117	Antagonist treatment is just as effective as replacement therapy for opioid addiction but neither is used often enough. <b>2018</b> , 23, 113-116		
116	Willis-Ekbom disease/restless legs syndrome in patients with opioid withdrawal. <b>2018</b> , 45, 39-43		8
115	Buprenorphine in Neonatal Abstinence Syndrome. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 103, 112-119	6.1	15
114	Opioids in Breast Milk: Pharmacokinetic Principles and Clinical Implications. <b>2018</b> , 58 Suppl 10, S151-S163		23
113	Voriconazole greatly increases the exposure to oral buprenorphine. <b>2018</b> , 74, 1615-1622		9
112	Opiate Drugs with Abuse Liability Hijack the Endogenous Opioid System to Disrupt Neuronal and Glial Maturation in the Central Nervous System. <b>2017</b> , 5, 294		20
111	Pain Therapy Guided by Purpose and Perspective in Light of the Opioid Epidemic. <b>2018</b> , 9, 119		56
110	Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option. <b>2018</b> , 78, 1211-1228		52
109	The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review. <b>2018</b> , 19,		38
108	Rapid, hydrolysis-free, dilute-and-shoot method for the determination of buprenorphine, norbuprenorphine and their glucuronides in urine samples using UHPLC-MS/MS. <b>2019</b> , 166, 236-243		5
107	The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence. <b>2019</b> , 86, 502-511		23
106	Opioids: A Review of Pharmacokinetics and Pharmacodynamics in Neonates, Infants, and Children. <b>2019</b> , 44, 591-609		33



105	Chronic High-Dose Buprenorphine Does Not Block Subjective High from Diacetylmorphine in a Patient in Heroin-Assisted Treatment. <b>2019</b> , 51, 377-382	5
104	Perioperative buprenorphine: are we asking the right questions?. <b>2019</b> , 44, 537-539	0
103	Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid-dependent, human immunodeficiency virus seronegative participants. <b>2019</b> , 85, 1771-1780	7
102	Suboxone Treatment and Recovery Trial (STAR-T): Study Protocol for a Randomised Controlled Trial of Opioid Medication Assisted Treatment with Adjunctive Medication Management Using Therapeutic Drug Monitoring and Contingency Management. <b>2019</b> , 2019, 2491063	3
101	Elective Naloxone-Induced Opioid Withdrawal for Rapid Initiation of Medication-Assisted Treatment of Opioid Use Disorder. <b>2019</b> , 74, 430-432	7
100	Sustained-release subdermal buprenorphine implants: the future of opioid use disorder management?. <b>2019</b> , 49, 41-49	0
99	Medications for management of opioid use disorder. <b>2019</b> , 76, 1097-1103	24
98	Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations. <b>2019</b> , 13, 93-103	45
97	State-of-The-Art Treatment of Opioid Use Disorder. <b>2019</b> , 91-104	
96	DARK Classics in Chemical Neuroscience: Opium, a Friend or Foe. <b>2019</b> , 10, 182-189	5
95	Treatment of opioid dependence with buprenorphine/naloxone sublingual tablets: A phase 3 randomized, double-blind, placebo-controlled trial. <b>2019</b> , 11, e12344	7
94	Use of generally recognized as safe or dietary compounds to inhibit buprenorphine metabolism: potential to improve buprenorphine oral bioavailability. <b>2019</b> , 40, 18-31	6
93	Continuing war on pain: a personalized approach to the therapy with nonsteroidal anti-inflammatory drugs and opioids. <b>2019</b> , 16, 171-184	11
92	Perioperative Management of Buprenorphine: Solving the Conundrum. <b>2019</b> , 20, 1395-1408	24
91	Pharmacokinetics and physiologic/behavioral effects of buprenorphine administered sublingually and intravenously to neonatal foals. <b>2019</b> , 42, 26-36	1
90	Buprenorphine Maintenance Subjects Are Hyperalgesic and Have No Antinociceptive Response to a Very High Morphine Dose. <b>2019</b> , 20, 119-128	20
89	Buprenorphine-cannabis interaction in patients undergoing opioid maintenance therapy. <b>2021</b> , 271, 847-856	6
88	Changes in fentanyl demand following naltrexone, morphine, and buprenorphine in male rats. <b>2020</b> , 207, 107804	6

87	Monitoring Prenatal Exposure to Buprenorphine and Methadone. <b>2020</b> , 42, 181-193	6
86	Buprenorphine is a weak dopamine releaser relative to heroin, but its pretreatment attenuates heroin-evoked dopamine release in rats. <b>2020</b> , 40, 355-364	2
85	Adjuncts to Local Anesthetics for Peripheral Nerve Blocks: A Review of Current Literature. <b>2020</b> , 35, 1-9	
84	Opioid and neuroHIV Comorbidity - Current and Future Perspectives. <b>2020</b> , 15, 584-627	9
83	Effect of Sleeve Gastrectomy on Buprenorphine Pharmacokinetics: A Planned Case Observation. <b>2020</b> , 42, 2232-2237	2
82	Dispersive solid-phase extraction of buprenorphine from biological fluids using metal-organic frameworks and its determination by ultra-performance liquid chromatography. <b>2020</b> , 43, 3045-3052	5
81	Prolonged-release buprenorphine formulations: Perspectives for clinical practice. <b>2020</b> , 75, 397-406	8
80	Scalable in silico Simulation of Transdermal Drug Permeability: Application of BIOiSIM Platform. <b>2020</b> , 14, 2307-2317	7
79	Chronic prescription opioid use predicts stabilization on buprenorphine for the treatment of opioid use disorder. <b>2020</b> , 117, 108073	6
78	A comprehensive review of partial opioid agonists for the treatment of chronic pain. <b>2020</b> , 34, 449-461	9
77	Pain interventions in adults with intellectual disability: A scoping review and pharmacological considerations. <b>2020</b> , 24, 875-885	4
76	A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain. <b>2020</b> , 9, 41-54	31
75	In vitro profiling of opioid ligands using the cAMP formation inhibition assay and the $\beta$ -arrestin2 recruitment assay: No two ligands have the same profile. <b>2020</b> , 872, 172947	4
74	Opioids and Cannabinoids for Osteoarthritis: Either, Both, or Neither. <b>2020</b> , 6, 29-44	
73	Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. <b>2020</b> , 13,	111
72	Classics in Chemical Neuroscience: Buprenorphine. <b>2020</b> , 11, 1385-1399	4
71	Auricular neural stimulation as a new non-invasive treatment for opioid detoxification. <b>2020</b> , 6, 7	11
70	Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials. <i>Clinical Pharmacokinetics</i> , <b>2021</b> , 60, 527-540	6.2 5

69	Relative addictive potential of opioid analgesic agents. <b>2021</b> , 11, 201-215	2
68	Physiologic Indirect Response Modeling to Describe Buprenorphine Pharmacodynamics in Newborns Treated for Neonatal Opioid Withdrawal Syndrome. <i>Clinical Pharmacokinetics</i> , <b>2021</b> , 60, 249-259	4
67	Acute Pain Management in Patients with Opioid Dependence. <b>2021</b> , 165-185	
66	Available Agents: Contraindications and Potential Drug-Drug Interactions. <b>2021</b> , 43-74	
65	Impact of the Opioid Epidemic on Drug Testing. <b>2021</b> , 43, 14-24	1
64	Transdermal delivery of buprenorphine from reduced graphene oxide laden hydrogel to treat osteoarthritis. <b>2021</b> , 32, 874-885	5
63	Opioid Treatment for Neonatal Opioid Withdrawal Syndrome: Current Challenges and Future Approaches. <b>2021</b> , 61, 857-870	6
62	Evaluation of Drug-Drug Interaction Liability for Buprenorphine Extended-Release Monthly Injection Administered by Subcutaneous Route. <b>2021</b> , 10, 1064-1074	1
61	Whole Genome Interpretation for a Family of Five. <b>2021</b> , 12, 535-123	0
60	Buprenorphine alters microglia and astrocytes acutely following diffuse traumatic brain injury. <b>2021</b> , 11, 8620	4
59	Clearance of buprenorphine during pregnancy and neonatal outcomes. <b>2021</b> , 24, 933-939	
58	Clinical pharmacology and dosing regimen optimization of neonatal opioid withdrawal syndrome treatments. <b>2021</b> , 14, 1231-1249	0
57	Determination of buprenorphine, norbuprenorphine, naloxone, and their glucuronides in urine by liquid chromatography-tandem mass spectrometry. <b>2021</b> , 13, 1658-1667	1
56	Buprenorphine-Related Deaths in North Carolina from 2010 to 2018. <b>2021</b> , 45, 780-791	2
55	Effects of opioid rotation to buprenorphine/naloxone on pain, pain thresholds, pain tolerance, and quality of life in patients with chronic pain and opioid use disorder. <b>2021</b> ,	0
54	Can buprenorphine be used for opioid use disorder during pregnancy?. <b>2021</b> , 34, 19-20	
53	Evaluation of Buprenorphine Rotation in Patients Receiving Long-term Opioids for Chronic Pain: A Systematic Review. <b>2021</b> , 4, e2124152	1
52	Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors. <b>2021</b> , 12, 828-870	5

51	Modeling SARS-CoV-2 infection in individuals with opioid use disorder with brain organoids. <b>2021</b> , 12, 2041731420985299	2
50	Buprenorphine for Pain and Opioid Dependence. <b>2015</b> , 311-318	2
49	Opioids. <b>2007</b> , 635-658	2
48	Cannabis Ontologies I: Conceptual issues with Cannabis and cannabinoids terminology. <b>2020</b> , 6, 205032452094579	4
47	Withdrawal from Buprenorphine/Naloxone and Maintenance with a Natural Dopaminergic Agonist: A Cautionary Note. <b>2013</b> , 4,	59
46	Perioperative Management of Patients on Buprenorphine and Methadone: A Narrative Review. <b>2020</b> , 37, 247-252	1
45	Intolerance of uncertainty and conditioned place preference in opioid addiction. <b>2018</b> , 6, e4775	6
44	Opioids for chronic pain management in patients with dialysis-dependent kidney failure. <b>2021</b> ,	1
43	Opiates and Opioids. <b>2008</b> , 367-374	
42	[Interactions with methadone and buprenorphine]. <b>2009</b> , 129, 2364-6	
41	OPIOID RECEPTOR AGONISTS AND ANTAGONISTS. <b>2010</b> , 1-164	
40	Pharmacogenetics in Clinical and Forensic Toxicology: Opioid Overdoses and Deaths. <b>2012</b> , 3-22	1
39	Opioid Addiction: Short- and Long-Acting Opioids. <b>2015</b> , 467-500	1
38	Analgetika. <b>2015</b> , 417-651	
37	Managing patients with chronic pain and opioid addiction. <b>2015</b> , 39-68	
36	Special population: Pregnancy, pain and addiction. <b>2015</b> , 69-82	
35	Pharmakologische Aspekte der intrauterinen Drogenexposition und klinische Konsequenzen. <b>2017</b> , 21-38	
34	Analgetika. <b>2018</b> , 447-696	

33	Spezifische Aspekte der Arzneimitteltherapie in der Palliativmedizin. <b>2018</b> , 1-81		
32	[Prolonged-release buprenorphine formulations: Perspectives for clinical practice]. <b>2020</b> ,		1
31	Drug Interactions. <b>2022</b> , 45-71		
30	Drug-drug interactions with direct-acting antivirals: when do we need to care?. <b>2020</b> , 86-93		
29	Mise au point sur la prise en charge de la douleur chez les patients adultes atteints de déficience intellectuelle. <i>Douleur Et Analgesie</i> , <b>2020</b> , 33, 41-48	0.2	
28	Physiologically-Based Pharmacokinetic Modeling to Investigate the Effect of Maturation on Buprenorphine Pharmacokinetics in Newborns with Neonatal Opioid Withdrawal Syndrome. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> ,	6.1	2
27	Optimization of patients with chronic pain and previous opioid use disorders.. <i>International Anesthesiology Clinics</i> , <b>2022</b> , 60, 48-55	0.6	
26	Methadone Distribution Trends from 2017-2019 in the United States.		
25	Oxymorphone Extended-Release Tablets (Opana ER) For the Management of Chronic Pain: A Practical Review for Pharmacists. <i>P and T</i> , <b>2010</b> , 35, 324-57	1.4	2
24	Update on the clinical use of buprenorphine: in opioid-related disorders. <i>Canadian Family Physician</i> , <b>2012</b> , 58, 37-41	0.9	32
23	Synthetic Urines in a Buprenorphine Clinic. <i>Kansas Journal of Medicine</i> , <b>2019</b> , 12, 146-147	0.6	
22	Treating Chronic Pain with Buprenorphine-The Practical Guide. <i>Current Treatment Options in Oncology</i> , <b>2021</b> , 22, 116	5.4	0
21	Aidi injection altered the activity of CYP2D4, CYP1A2, CYP2C19, CYP3A2, CYP2E1 and CYP2C11 in normal and diethylnitrosamine-induced hepatocellular carcinoma in rats.. <i>Journal of Ethnopharmacology</i> , <b>2021</b> , 286, 114930	5	1
20	Transition from Oxycodone to Buprenorphine/Naloxone in a Hospitalized Patient with Sickle Cell Disease: A Case Report.. <i>Journal of General Internal Medicine</i> , <b>2022</b> , 37, 1281	4	1
19	Buprenorphine withdrawal induced takotsubo cardiomyopathy: A series of unfortunate events.. <i>Journal of Cardiology Cases</i> , <b>2022</b> , 25, 316-318	0.6	0
18	Analgetika. <b>2022</b> , 511-774		
17	Buprenorphine, Polydrug Use and Deaths. <b>2022</b> , 1-20		
16	Spezifische Aspekte der Arzneimitteltherapie in der Palliativmedizin. <b>2022</b> , 1-108		

15	An update on the physiologic changes during pregnancy and their impact on drug pharmacokinetics and pharmacogenomics. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , <b>2021</b> ,	1.6	2
14	Buprenorphine and Cardiac Surgery: Navigating the Challenges of Pain Management. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , <b>2022</b> ,	2.1	
13	Role of Buprenorphine in Chronic Pain Management in Covid-19. <i>International Journal of Advanced Research in Science, Communication and Technology</i> , 818-822	0.5	
12	Lower buprenorphine elimination rate constant is associated with lower opioid use.		
11	Buprenorphine and its formulations: a comprehensive review. <b>2022</b> , 10,		
10	A Critical Review on the Pharmacodynamics and Pharmacokinetics of Non-steroidal Anti-inflammatory Drugs and Opioid Drugs Used in Reptiles. <b>2022</b> , 17, 100267		1
9	Pharmacodynamic model of slow reversible binding and its applications in pharmacokinetic/pharmacodynamic modeling: review and tutorial. <b>2022</b> , 49, 493-510		0
8	Buprenorphine reduces methamphetamine intake and drug seeking behavior via activating nociceptin/orphanin FQ peptide receptor in rats. 13,		1
7	Buprenorphine, Polydrug Use, and Deaths. <b>2022</b> , 2863-2882		0
6	What's the buzz about buprenorphine? A pharmacologic overview. <b>2022</b> , 20, 10-18		0
5	An evaluation method for developing abuse-deterrent opioid formulations with agonist and antagonist combinations using conditioned place preference. <b>2023</b> , 639, 100-105		0
4	¶We want everything in a one-stop shop¶acceptability and feasibility of PrEP and buprenorphine implementation with mobile syringe services for Black people who inject drugs. <b>2022</b> , 19,		0
3	Buprenorphine administration during gestation induces hepatotoxicity in the rat fetus.		0
2	Abuse of Prescription Buprenorphine, Regulatory Controls and the Role of the Primary Physician. <b>2006</b> , 35, 492-495		3
1	Complications Relating to Intravenous Buprenorphine Abuse: A Single Institution Case Series. <b>2006</b> , 35, 487-491		1